We have exemplified our findings with KRAS-positive colon cancer cells, Myc-amplified neuroblastoma (N-Myc-driven) and confirmed sensitivity of combination therapy in B cell lineage (C-Myc-driven). This evidence concerns the gene KRAS and malignant colon neoplasm.